

JAN 28 2026

---

# A BILL FOR AN ACT

RELATING TO DRUGS FOR WEIGHT LOSS.

**BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:**

1       SECTION 1. The legislature finds that glucagon-like  
2 peptide-1 drugs, commonly known as GLP-1 drugs, have been used  
3 for decades as an effective treatment for type 2 diabetes  
4 mellitus, and drug insurance policies generally provide coverage  
5 for these medications when prescribed for that purpose. In  
6 recent years, GLP-1 drugs have also gained significant attention  
7 for their effectiveness in treating obesity. However, due to  
8 their high cost, insurance coverage for GLP-1 drugs prescribed  
9 for obesity remains relatively limited in Hawaii. In addition,  
10 while state medicaid programs must cover nearly all drugs  
11 approved by the United States Food and Drug Administration for  
12 medically accepted indications, a long-standing statutory  
13 exception under 42 United States Code section 1396r-8(d) (2) (A)  
14 allows states to choose whether to provide medicaid coverage for  
15 weight-loss drugs for adults. As a result, although the United  
16 States Food and Drug Administration has approved the GLP-1 drugs  
17 Saxenda (liraglutide), Wegovy (semaglutide), and Zepbound



1 (tirzepatide) for purposes of weight loss, the State of Hawaii  
2 department of human services has opted to exclude these  
3 medications from coverage under medicaid and medicare part D in  
4 most situations.

5 The legislature believes that GLP-1 drugs should be covered  
6 for weight loss purposes, because GLP-1 drugs are effective for  
7 addressing obesity, a major health issue linked to diabetes,  
8 heart disease, and other conditions. Addressing one of the  
9 major contributors to disease will help lower overall healthcare  
10 costs for everyone.

11 Accordingly, the purpose of this Act is to require the  
12 department of human services to remove the coverage exclusion  
13 for glucagon-like peptide-1 drugs that have been approved by the  
14 United States Food and Drug Administration for weight loss  
15 purposes, thereby allowing medicaid and medicare part D coverage  
16 for certain glucagon-like peptide-1 drugs to treat obesity.

17 SECTION 2. (a) No later than August 1, 2026, the  
18 department of human services shall issue temporary rules without  
19 regard to chapter 91, Hawaii Revised Statutes, to effectuate  
20 subsection (c). The temporary rules shall be effective until  
21 amended or superseded by the rules adopted under subsection (b).



1 (b) No later than January 1, 2028, the department of human  
2 services shall adopt rules under chapter 91, Hawaii Revised  
3 Statutes, to effectuate subsection (c).

4 (c) Any patient who is a medicaid or medicare part D  
5 prescription drug program recipient shall be eligible for  
6 coverage of glucagon-like peptide-1 drugs as agents when used  
7 for weight loss; provided that:

8 (1) The glucagon-like peptide-1 drug is approved by the  
9 United States Food and Drug Administration for  
10 purposes of weight loss;

11 (2) The glucagon-like peptide-1 drug is prescribed by a  
12 practitioner; and

13 (3) Prior authorization shall not be required.

14 For purposes of this Act, "practitioner" shall have the  
15 same meaning as in section 461-1, Hawaii Revised Statutes.

16 SECTION 3. There is appropriated out of the general  
17 revenues of the State of Hawaii the sum of \$ or so much  
18 thereof as may be necessary for fiscal year 2026-2027 for  
19 medicaid and medicare coverage of glucagon-like peptide-1 drugs  
20 as agents for weight loss.



# S.B. NO. 3195

1       The sum appropriated shall be expended by the department of  
2 human services for the purposes of this Act.

3       SECTION 4. This Act shall take effect on July 1, 2026.

4

INTRODUCED BY: Kurt Fevella



# S.B. NO. 3195

**Report Title:**

DHS; Weight Loss; Obesity; Medicare; Medicaid; GLP-1;  
Appropriation

**Description:**

Requires the Department of Human Services to provide Medicaid and Medicare part D prescription drug program recipients with coverage of glucagon-like peptide-1 (GLP-1) drugs for weight loss. Appropriates funds.

*The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.*

